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Abstract: Endometriosis is a common gynecological disease affecting 6%–10% of women 
of reproductive age and is characterized by the presence of endometrial-like tissue in 
localizations outside of the uterine cavity as, e.g., endometriotic ovarian cysts. Mainly, two 
epithelial ovarian carcinoma subtypes, the ovarian clear cell carcinomas (OCCC) and the 
endometrioid ovarian carcinomas (EnOC), have been molecularly and epidemiologically 
linked to endometriosis. Mutations in the gene encoding the AT-rich interacting domain 
containing protein 1A (ARID1A) have been found to occur in high frequency in OCCC and 
EnOC. The majority of these mutations lead to a loss of expression of the ARID1A protein, 
which is a subunit of the SWI/SNF chromatin remodeling complex and considered as a 
bona fide tumor suppressor. ARID1A mutations frequently co-occur with mutations, 
leading to an activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, such as 
mutations in PIK3CA encoding the catalytic subunit, p110α, of PI3K. In combination with 
recent functional observations, these findings strongly suggest cooperating mechanisms 
between the two pathways. The occurrence of ARID1A mutations and alterations in the 
PI3K/AKT pathway in endometriosis and endometriosis-associated ovarian carcinomas, as 
well as the possible functional and clinical implications are discussed in this review. 
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1. Introduction 
The identification of recurrent somatic mutations in endometriosis-associated ovarian cancer, in 
particular, AT-rich interacting domain containing protein 1A (ARID1A) mutations [1,2], provided the 
first molecular evidence of a direct pathogenic link between endometriosis and certain subtypes of 
ovarian carcinomas [3,4]. 
Endometriosis is a common gynecological inflammatory disease that affects at least 6%–10% of 
women of reproductive age and is characterized by the presence of endometrial-like tissue outside of 
the uterine cavity [5,6]. The prevalence of this disease is higher in women with abdominal pain, 
infertility or both, where it rises to an incidence rate of 35%–50% [7]. The ectopic endometrial-like 
tissue is most often found in the pelvic peritoneum, the ovaries and/or the rectovaginal septum, but can 
also involve uncommon localizations, such as the diaphragm, pleura, pericardium or, even,  
brain [7,8]. The exact pathogenesis of endometriosis has as yet not been fully elucidated. One of the 
most widely accepted theories is the retrograde menstruation of fragments of menstrual endometrium 
through the fallopian tubes that may explain the more frequent cases of peritoneal and ovarian 
endometriosis [5]. The typical clinical symptoms of the disease consist of dysmenorrhea, dyspareunia 
and infertility. Current treatment options are the surgical removal of endometriotic implants and 
hormonal suppressant drugs [8]. The overall risk of ovarian cancer associated with endometriosis can 
be regarded as generally very low [9], but is still increased compared to women not presenting  
with endometriosis [8]. 
Clinical suggestion for a causal relationship between endometriosis and ovarian cancer is not novel, 
and the possible pathogenic link had already been described at the beginning of the 20th century by 
Sampson [10]. However, larger epidemiological studies showing evidence for a causal relationship 
between endometriosis and ovarian cancer were lacking until the end of the 20th century [11]. 
In a large registry study among 20,686 women in Sweden who had been hospitalized for 
endometriosis, a significantly increased risk for ovarian cancer (standardized incidence ratio (SIR) 1.9, 
95% confidence interval (CI) 1.3–2.8) was found after a mean of 11.4 years of follow-up. The risk of 
ovarian cancer was increased 2.5-fold in women with a follow-up of more than 10 years [12]. A larger 
Swedish register study involving 64,492 women with endometriosis confirmed an elevated risk of 
ovarian cancer in these patients with an SIR of 1.43 (95% CI 1.19–1.71). The risk of ovarian cancer 
was considerably higher in patients with early diagnosed and long-standing endometriosis (SIR 2.01 
and 2.23, respectively) [13]. Several other studies have also described an increased risk of ovarian 
cancer in women with endometriosis [14–24]. A large epidemiological pooled analysis of 13  
case-control studies, including 13,226 controls and 7911 women with invasive ovarian cancer, 
investigated the frequency of self-reported endometriosis and found significantly increased risks for 
ovarian cancer in women with history of endometriosis with an odds ratio of 1.46 (95% CI 1.31–1.63, 
p < 0.0001) after stratifying for age, ethnic origin and adjustment for the duration of oral contraceptive 
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use and parity. Importantly, a significant association of the histological subtypes of clear-cell (OR 3.05, 
95% CI 2.43–3.84, p < 0.0001), endometrioid (OR 2.04, 95% CI 1.67–2.48, p < 0.0001), and low-grade 
serous ovarian carcinomas (OR 2.11, 95% CI 1.39–3.20, p < 0.0001) was found with endometriosis in 
this study. In contrast, there was no association of endometriosis with mucinous and high-grade serous 
cancer, as well as borderline tumors [25]. 
Ovarian cancer is the most lethal gynecological neoplasm and a very heterogeneous disease [26]. 
Based on extensive morphologic, immunohistochemical and molecular genetic analyses of different 
epithelial ovarian cancer subtypes, Kurman and Shih proposed that epithelial ovarian carcinomas can 
be divided in two groups: Type I ovarian carcinomas comprise clear cell carcinomas (OCCC),  
low-grade endometrioid carcinomas (EnOC), mucinous carcinomas and low-grade serous carcinomas. 
They tend to be rather slow-growing, low-grade neoplasms and often develop in a stepwise manner 
from visible precursor lesions. On a molecular level, they often share mutations in different genes, 
such as KRAS, BRAF, PTEN, PIK3CA, ARID1A, ERBB2, CTNNB1 and PPP2R1A. Type II ovarian 
carcinomas mainly cover high-grade serous carcinomas and are more frequent, as they represent 
approximately 75% of all ovarian carcinomas. These tumors are characterized by aggressive behavior, 
nearly ubiquitous presence of TP53 mutations and a high level of genetic instability, in contrast to type 
I tumors, which rarely show TP53 mutations [27–31]. 
There is growing evidence that epithelial ovarian carcinomas, unlike ovarian germline tumors, may 
often find their origin in non-ovarian tissue [32,33]. This is a shift of paradigms, since until recently, 
the largely accepted theory was that ovarian epithelial tumors arise from the single cell layer lining the 
ovarian surface, usually referred to as surface epithelium [34,35]. Hence, numerous molecular studies 
indicate that the precursor of serous ovarian carcinomas may be localized in the epithelium  
of the fallopian tubes in the form of a precursor lesion, called serous tubal intraepithelial  
carcinoma [27,32,36–42]. Epidemiologic data are supporting this theory, since it has been reported  
that the risk of ovarian cancer decreases after tubal ligation or excision [43–46]. 
Two distinct histological subtypes of ovarian carcinomas, the OCCC and EnOC, have been directly 
associated with endometriosis through observational epidemiological studies [14,24,25,47–49]. 
Atypical endometriosis has long been proposed as the histological precursor lesion of OCCC and 
EnOC [50,51]. A direct pathogenic link of endometriosis with OCCC and EnOC has been evidenced 
by the important study of Wiegand et al. demonstrating common truncating mutations and loss of 
protein expression of the ARID1A tumor suppressor gene in OCCC and contiguous atypical 
endometriosis [1]. Whole-exome sequencing performed independently by Jones et al. in eight OCCC 
confirmed frequent mutations of ARID1A, as well as PIK3CA, PP2R1A and KRAS. Validation of these 
results in 42 OCCC (the eight tumors of the discovery cohort and an additional 34 OCCC samples as a 
validation cohort) by Sanger sequencing reported the frequencies of these mutations at 57%, 40%, 
7.1% and 4.7%, respectively [2]. 
OCCC is the second most common epithelial ovarian cancer subtype, and its prevalence has been 
shown to differ significantly between geographic regions [52]. The highest prevalence is described in 
Asian countries, especially in Japan, where it accounts for 15%–25% of epithelial ovarian  
cancer [53,54]. The prevalence in Europe and North America is significantly lower, where it accounts 
for 1%–13% of ovarian epithelial tumors [55–58]. Interestingly, the prevalence of endometriosis has 
also been reported to be higher in Asian women in some studies [59]. OCCC are reported to occur at 
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an earlier age than serous ovarian cancer, with a median age at diagnosis of 55 years compared to  
64 years [58]. Although low-stage OCCC have a relatively good prognosis, high-stage OCCC have a 
poorer prognosis than stage-matched high-grade serous ovarian carcinomas and are often characterized 
by resistance to standard carboplatin paclitaxel chemotherapy [53,54,60–64]. Interestingly, OCCC are 
associated with a 2.5-fold higher incidence of clinically significant venous thromboembolism than in 
women with other histological types of epithelial ovarian cancer [65]. 
The prevalence of EnOC is estimated to be somewhat lower than in OCCC and accounts for  
7%–13% of epithelial ovarian cancer [56,66,67]. There is an association of endometrioid ovarian 
carcinomas with uterine endometrial carcinomas in 15%–20% of cases [68–72]. Similarly to OCCC, 
EnOC are often diagnosed as early-stage disease in younger women (median age 47 years) in 
comparison with serous ovarian cancer and, often, become manifest with pelvic pain, a palpable 
abdominal mass, abnormal vaginal bleeding and/or newly developed or increased dysmenorrhea  
and dyspareunia [48,73]. 
Finally, seromucinous borderline tumors have also been associated with endometriosis. They are a 
rare subtype of mucinous borderline tumors and show a distinct non-gastrointestinal-type pattern [67]. 
These tumors coexist with endometriosis in 30%–70% and are likely to originate from endometriotic 
cysts [67,74–76]. 
This review focuses on common genetic alterations in endometriosis and the endometriosis-associated 
OCCC and EnOC, with special emphasis on ARID1A mutations and alterations in the PI3K/AKT 
pathway and potential cooperative mechanisms between these pathways. 
2. ARID1A Mutations 
2.1. Background 
The ARID1A gene encodes the AT-rich interacting domain containing protein 1A (ARID1A), also 
known inter alia as BAF250a or p270, which is part of a family of 15 proteins in humans that all 
contain a characteristic 100-amino acid DNA-binding ARID domain that binds in a sequence  
non-specific manner to DNA [77]. The ARID1 subfamily is a member of seven ARID subfamilies 
based on degree of homology of the ARID domain and the similarity between the highly variable  
non-ARID domain structures [78]. ARID1A and ARID1B are the only ARID1 subfamily members and 
are two mutually exclusive subunits of the SWI/SNF chromatin remodeling complex [79]. It is through 
this complex that ARID1A probably exerts its role as a tumor suppressor [80]. ARID1A is located at 
1p36.11 [81] and encodes a large protein of approximately 250 kD that is expressed primarily (maybe 
exclusively) in the nucleus [77]. Its expression is cell-cycle dependent and is higher in the G0/G1-phase 
compared to the S- and G2/M-phases [82]. ARID1A encodes two protein isoforms (2285 and 2086 
amino acids), but there is no actual knowledge about a functional difference of the two isoforms. It has 
been described that ARID1A is post-translationally modified through lysine acetylation and 
serine/threonine phosphorylation, which may potentially regulate protein expression or protein-protein 
interactions [77,83]. Although its role as a part of the SWI/SNF complex is the best studied interaction 
of the ARID1A protein, several other protein-protein interactions, such as interactions with p53 [84], 
with SMAD3 [84], with hormonal receptors, such as the glucocorticoid receptor [85], and others have 
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been described. Due to its various interactions, the understanding about the functional effects of 
ARID1A mutations remains quite poor and may vary depending on different cell types. Other 
components of the ATP-dependent SWI/SNF chromatin remodeling complex, such as SMARCB1, 
have been found to be mutated in a wide variety of cancers [77]. The frequency of mutations of the 
different components of the SWI/SNF complex typically differs among different cancers [86]. 
Mutations in the ARID1A gene occur in a wide variety of different cancers. They have been found 
to be the most frequent in OCCC, followed by EnOC, but occur ubiquitously in various cancers [86]. 
Frequent mutations or loss of expression of ARID1A have also been found in endometrial carcinomas 
of endometrioid (loss of expression in 29%), clear cell (loss of expression in 26%) and serous 
histology (loss of expression in 18%) [87,88], pancreatic (mutations in 8%–45%) [89,90] and gastric 
adenocarcinomas (mutations in 8%–29%) [91–93], as well as in hepatocellular (mutations in  
10%–17%) [94–96] and breast carcinomas (mutations in 4%–35%) [97,98]. 
2.2. ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas 
A high frequency of ARID1A mutations has been detected in endometriosis-associated ovarian 
carcinomas. Studies undertaken by Wiegand et al. [1] and by Jones et al. [2] have reported ARID1A 
mutations in 46%–57% of OCCC and in 30% of EnOC. In the study of Wiegand et al., validated 
RNA-sequencing results of 19 OCCC samples (18 solid OCCC tumor samples and one OCCC cell line 
(TOV21G)) reported three somatic nonsense mutations, two somatic insertion/deletion mutations, one 
somatic missense mutation (found simultaneously in a sample containing an insertion mutation) and 
one gene rearrangement of ARID1A with the neighboring gene, ZDHHC18, with the fusion ends 
mapping to a homozygous deletion involving most of ARID1A. These data were verified in a  
mutation-validation cohort of 210 samples of ovarian carcinomas, including 101 OCCC, 33 EnOC and 
76 high-grade serous ovarian carcinomas, as well as a second OCCC cell line (ES2) (cf. Table 1). All 
the 65 truncating ARID1A mutations that were found in 47 OCCC and 8 EnOC samples were somatic. 
ARID1A is a large gene containing 20 exons, and the mutations found by Wiegand et al. were 
distributed evenly across the whole gene, with just a few recurrent mutations between different tumors. 
Most of the detected mutations were truncating (nonsense or frameshift) and correlated strongly with a 
loss of ARID1A protein expression in the immunohistochemistry (IHC). A total of 27 (73%) of the 37 
OCCC and five (50%) of 10 EnOC samples with ARID1A mutations showed loss of protein expression 
in IHC, whereas four (11%) of 36 OCCC and two (9%) of 23 EnOC samples without ARID1A 
mutations were negative for ARID1A protein expression. Since data from exon resequencing and RNA 
sequencing presented excellent correlation, there was no suggestion for a relevant epigenetic silencing  
of ARID1A [1]. 
It is interesting that only approximately 30% of the OCCC showed homozygous mutations of 
ARID1A, whereas 73% of heterozygous mutated tumors showed a loss of protein expression without 
loss of heterozygosity. Similar observations in other cancer types, as well as results of in vitro studies, 
therefore, suggest a haploinsufficient tumor suppressor role for ARID1A [1,77]. 
Jones et al. described 32 mutations in ARID1A that were also distributed throughout the coding 
region of ARID1A and were all predicted to truncate the protein (nine nonsense and 23 
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insertion/deletion mutations). Both ARID1A alleles were affected through loss of heterozygosity or 
through biallelic mutations in 10 of the 24 tumors harboring ARID1A mutations [2]. 
The frequency of loss of ARID1A protein expression in OCCC and EnOC was verified in multiple 
studies [99–104] and found to be consistent with the initial observations [1,2]. Due to the high 
frequency of their occurrence, mutations of ARID1A are regarded to be one of the major genetic 
alterations in endometriosis-associated OCCC and EnOC [67]. 
An overview of the studies that analyzed ARID1A expression in ovarian cancer by mutational 
analysis and/or immunohistochemistry is given in Table 1. 
Table 1. Studies that investigated AT-rich interacting domain containing protein 1A 
(ARID1A) mutations and protein expression in ovarian cancer with sequencing methods 
and by immunohistochemistry (IHC). OCCC, ovarian clear cell carcinomas; EnOC, 
endometrioid ovarian carcinomas. 
Authors, year of 
publication 
Ovarian carcinoma subtypes Loss of ARID1A protein expression 
ARID1A mutations by sequencing 
methods 
Ref. 
Jones et al., 2010 
42 OCCC - 57% somatic ARID1A mutations in a total 
of 42 OCCC 
[2] 
Wiegand et al., 
2010 
18 OCCC tumor samples and 1 
OCCC cell line (whole 
transcriptome)—discovery cohort 
 
210 ovarian carcinomas and a 
second OCCC cell line 
(ARID1A sequencing); 
mutation validation cohort 
 
455 ovarian carcinomas  
(IHC validation cohort) 
Loss of ARID1A protein expression 
correlated strongly with the presence 
of ARID1A mutations in the mutation 
discovery and validation cohort. 
 
 
 
 
 
Loss of ARID1A protein expression 
in 55 (42%) of 132 OCCC, 39 (31%) 
of 125 EnOC, and 12 (6%) of 198 
high-grade serous ovarian carcinomas. 
Somatic ARID1A mutations (3 nonsense,  
2 insertion/deletion, 1 missense and 1 gene 
rearrangement) in the discovery cohort 
 
ARID1A mutations in 55 of 119 OCCC 
(46%), 10 of 33 EnOC (30%) and none of 
the 76 high-grade serous  
ovarian carcinomas 
[1] 
Maeda et al., 
2010 
OCCC Negative ARID1A expression in 88 of 
149 (59%) OCCC tumor samples  
by IHC 
Sequencing of 12 OCCC tumor samples;  
9 samples with ARID1A mutations and  
3 with wild-type expression 
[99] 
Guan et al., 2011 
serous and mucinous OC No loss of ARID1A expression in 221 
high-grade serous, 15 low-grade serous, 
and 36 mucinous ovarian carcinomas 
No ARID1A mutations detected in 32  
high-grade serous, 19 low-grade serous and 
5 mucinous ovarian carcinomas 
[88] 
Katagiri et al., 
2011 
OCCC Loss of ARID1A expression in 9 
(15%) of 60 OCCC 
- 
[100] 
Yamamoto et al., 
2012 
OCCC Loss of ARID1A expression in 23 
(55%) of 42 OCCC 
- 
[101] 
Yamamoto et al., 
2012 
90 cases of primary OCCC 
(including 42  
previously examined) 
Loss of ARID1A expression in 44% 
of 90 OCCC samples 
- 
[102] 
Lowery et al., 
2012 
212 OCCC and EnOC Loss of ARID1A expression in 34 (41%) 
of 82 OCCC and 62 (48%) of 130 EnOC 
- 
[103] 
Samartzis et al., 
2012 
136 ovarian cancer samples as 
study control (23 OCCC,  
28 EnOC, 63 serous ovarian 
carcinomas, 15 mucinous 
ovarian carcinomas) 
Loss of ARID1A expression in 5 
(22%) of 23 OCCC, 13 (46%) of 28 
EnOC, 7 (11%) of 63 serous ovarian 
carcinomas, 4 (27%) of 15 mucinous 
ovarian carcinomas 
- 
[104] 
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2.3. Loss of ARID1A Expression in Endometriosis 
Mutations of ARID1A have been demonstrated in atypical endometriosis that, in contrast to the 
adjacent OCCC tissue, was negative for HNF-1β and retained estrogen receptor expression. This 
indicates that ARID1A mutations are an early event in the pathogenesis of endometriosis-associated 
ovarian carcinomas. In contrast to tumor-adjacent atypical endometriosis, no mutations or loss of 
ARID1A expression were found in the distal non-atypical endometriotic tissue of the same patients [1]. 
Table 2. Studies investigating ARID1A mutations and protein expression in endometriosis. 
Authors, year of 
publication 
Endometriosis samples Loss of ARID1A protein expression 
ARID1A mutations by 
sequencing 
Ref. 
Wiegand et al., 
2010 
Two cases with atypical endometriosis 
adjacent to ARID1A-deficient OCCC 
(adjacent and distant endometriosis was 
investigated from both cases) 
In two patients, loss of ARID1A expression 
were evident in the tumor and contiguous 
atypical endometriosis, but not in distant 
endometriotic lesions 
ARID1A mutations in the 
tumor and contiguous 
atypical endometriosis, but 
not in distant endometriosis 
[1] 
Wiegand et al., 
2011 
10 cases of atypical endometriosis Loss of ARID1A expression in 1 of 10 samples 
in the atypical areas, with retention in  
non-atypical endometriosis 
- 
[87] 
Yamamoto et al., 
2012 
59 endometriotic lesions present in 90 
cases of OCCC (28 cases adjacent to 
tumor samples) 
Complete loss of ARID1A expression in  
28 endometriotic samples, of those,  
17 adjacent to tumor tissue 
- 
[102] 
Yamamoto et al., 
2012 
22 solitary benign endometriosis samples 
and 28 endometriosis samples (14  
non-atypical and 14 atypical) issuing 
from 17 patients with ARID1A-deficient 
endometriosis-associated  
ovarian carcinomas 
All the 22 non-tumor associated endometriosis 
samples were ARID1A positive; 12 (86%) of 
the 14 tumor associated non-atypical 
endometrioses were ARID1A-deficient,  
and all of the 14 atypical endometrioses were  
ARID1A-deficient 
- 
[101] 
Samartzis et al., 
2012 
74 samples of non-atypical 
endometriosis: ovarian (n = 27), 
peritoneal (n = 19); deep-infiltrating  
(n = 28); 30 samples of normal 
endometrium as control 
Complete lack of ARID1A expression was 
observed in three endometriomas (n = 3/20, 
15%) and one deep-infiltrating endometriosis 
sample (n = 1/22, 5%); in addition, clonal 
expression loss was observable in cases of 
partially negative ARID1A expression 
- 
[104] 
Ayhan et al., 
2012 
15 discrete endometriotic foci remote 
from endometriotic cyst and  
ovarian carcinoma; 
4 ovarian endometriomas without 
carcinoma and 6 cases of peritoneal 
endometriosis as controls 
All cases retained ARID1A expression - 
[105] 
Xiao et al., 2012 
36 cases of solitary ovarian endometriosis; 
normal eutopic endometrium as control 
Loss of ARID1A expression in 20% of benign 
endometriomas; normal endometrium retained 
ARID1A expression 
- 
[106] 
This observation sustains the theory of ARID1A being a tumor suppressor in which loss of 
expression occurs in cell clones that are undergoing a process of precancerous alteration. However, it 
remains controversial at which stage of pathogenesis ARID1A mutations occur in endometriosis, i.e., if 
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they are limited to atypical endometriosis or if they already occur in a low-frequent manner in  
non-atypical endometriosis or at the early transition stage from non-atypical to atypical endometriosis. 
To date, ARID1A sequencing studies are lacking in non-carcinoma-related endometriosis, probably 
due to the fact that the occurrence of ARID1A mutations is expected to be low in endometriosis 
(considering that the relative risk to developing ovarian cancer during a lifetime is approximately 
1.5%) and that ARID1A sequencing studies are technically challenging, due to the large size of the 
gene and the random distribution of the mutations along the gene. Nevertheless, immunohistochemical 
data from different studies indicated that loss of ARID1A expression is also observable in rare cases of 
non-atypical endometriosis, especially in endometriotic cysts of the ovary, also referred to as 
endometriomas [101,104,106]. An overview of the studies that investigated ARID1A expression in 
endometriosis with or without relation to ovarian carcinomas is given in Table 2. 
Despite the good correlation between the immunohistochemical negative ARID1A expression and 
its mutations (cf. Section 2.4.), it is not definitely clarified if these observations are the result of 
ARID1A mutations or epigenetic regulation. Sequencing analyses and further functional studies are 
warranted to elucidate the exact time point of the occurrence of ARID1A mutations and their role in 
(atypical) endometriosis. 
2.4. Correlation between ARID1A Mutations and Loss of ARID1A Expression  
in Immunohistochemistry 
In addition to Wiegand et al. [1], other groups found a strong correlation between ARID1A 
mutations and loss of ARID1A protein expression in different tumor types. Guan et al. [88], in 
addition to a large IHC analysis of 995 tumor samples of various localizations, sequenced ARID1A in a 
total of 93 tumor samples and found 10 (40%) of 25 uterine endometrioid carcinomas mutated (all of 
them insertion/deletion or nonsense mutations), whereas none (0%) of 12 uterine serous carcinomas 
and none (0%) of 56 ovarian serous and mucinous carcinomas revealed somatic mutations in ARID1A. 
They correlated the ARID1A status and IHC in the 25 uterine endometrioid carcinomas and in 51 
ovarian serous carcinomas and found a significant correlation of ARID1A expression with its 
mutational status (p = 0.0014). Interestingly, they found an immunohistochemical pattern of clonal loss 
in ARID1A mutated carcinomas, which was not found in ARID1A wild-type carcinomas. This clonal 
loss of ARID1A protein expression was observed in four cases, which were classified as 
immunohistochemically positive, but genetically harbored ARID1A mutations. When combining these 
cases with completely negative ones, they found an even stronger correlation of mutational status and 
IHC (p < 0.0001) [88]. In a smaller study performed in OCCC, there was a concordance of ARID1A 
immunohistochemistry in 91% of 12 OCCC cases with known ARID1A mutational status with a 
sensitivity of 100% and a specificity of 66% [99]. In gastric adenocarcinomas, Zang et al. found a 
reduced or absent ARID1A protein expression in 75% (6/8) of ARID1A mutated samples and a strong 
positivity for ARID1A protein expression in 100% (11/11) of the samples with wild-type ARID1A 
sequence [92]. Wang et al. sequenced ARID1A in a total of 109 gastric cancers. They found 32 
samples with ARID1A mutations, which, as discovered in OCCC and EnOC, were truncating in the 
majority of cases (85%). Seventy-five percent (24/32) of gastric cancers with ARID1A mutations 
immunohistochemically exhibited a loss or substantially lower ARID1A protein expression compared 
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to cancers with the wild-type gene (p < 0.001) [91]. Taken together, these results suggest that an 
immunohistochemical loss of ARID1A expression correlates well, although not perfectly, with 
truncating ARID1A mutations, which justifies its use as a surrogate marker for the underlying  
gene mutations [87,101,104,107–109]. 
3. PI3K/AKT-Pathway Alterations 
3.1. Introduction 
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway supports multiple 
mechanisms responsible for cancer progression, including proliferation, inhibition of apoptosis, cell 
adhesion and transformation. PI3K activation, e.g., by activating mutations of PIK3CA encoding the 
catalytic subunit, p110alpha, leads to an activation of AKT, a serine-threonine kinase, which is present 
in three different isoforms (AKT1-3) in human cancer and leads to increased cellular growth and 
survival of cancer cells [110]. The mammalian target of rapamycin complex 1 (mTORC1) is one of the 
major effectors downstream of AKT and is central in controlling cell growth and proliferation. 
mTORC1 was discovered through its inhibition by the drug, rapamycin [111,112]. Activation of the 
PI3K/AKT pathway is mainly effected by the activation of receptor tyrosine kinases and by somatic 
mutations in specific components of the signaling pathway. These mainly include loss of the tumor 
suppressor, PTEN, activating mutations of p110alpha (PIK3CA) and, less frequently, of the three 
isoforms of AKT1-3. In addition, amplifications of AKT1 and AKT2, as well as of PIK3CA have been 
described in some cancers, but seem to play a subordinate role compared to the other described 
mechanisms [110]. 
3.2. PI3K/AKT Pathway Activation in Endometriosis 
Several studies have reported PI3K/AKT pathway activation in endometriosis [113–120]. It has 
been shown that the PI3K/AKT pathway regulates FOXO1 protein levels, a member of the  
forkhead-box O family and the decidua-specific gene IGF binding protein-1 (IGFBP-1), which are 
both involved in the decidualization of endometrial cells. Levels of phospho-AKT (Ser473) were 
consistently higher in endometriotic stromal cells, and overactivation of PI3K/AKT led to reduced 
decidualization in primary endometriotic stromal cells issuing from endometriomas [113]. Reduced 
decidualization and IGFBP-1 secretion have also been observed in primary endometriotic cells from other 
localizations [121] and in eutopic endometrial stromal cells from women with endometriosis [122,123]. 
Decidualization of the endometrium is a remodeling event that is physiologically occurring in response 
to progesterone in the secretory phase of the menstrual cycle in order to prepare the endometrium for 
the implantation of the embryo [124]. It is known that progestins and cAMP decrease phosphorylated 
AKT levels and increase nuclear FOXO1 levels in eutopic endometrial stromal cells [125,126]. The 
response to decidual stimuli by medroxyprogesterone acetate and dibutyryl cAMP was dramatically 
lower in ectopic endometriotic stromal cells. Interestingly, both inhibition of PI3K and AKT led to 
increasing nuclear FOXO1 and IGFBP1 levels in response to treatment with medroxyprogesterone 
acetate and dibutyryl cAMP, supporting evidence that the increased PI3K/AKT pathway is involved in 
the reduced decidual response in endometriosis [113]. This observation is further interesting, since it 
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may indicate that the PI3K/AKT pathway is involved in processes supporting the effects of 
progesterone resistance, a well-described characteristic of endometriosis [127]. Therefore, small 
molecule inhibitors may be preclinically investigated as a therapeutic option, especially in overcoming 
progesterone resistance in endometriosis [113]. 
3.3. PI3K/AKT Pathway Alterations in OCCC and EnOC 
In contrast to high-grade serous ovarian carcinomas, where activation of the PI3K/AKT pathway 
through mutation of PIK3CA, AKT or inactivating mutations of PTEN is rather rare (< 5%), it is a 
clearly more frequent event in OCCC and EnOC [128]. Activating mutations in PIK3CA encoding 
p110α, the catalytic subunit of PI3K, have been described to occur in 33%–40% of OCCC [2,129]. 
Activation of the PI3K/AKT pathway by loss of PTEN expression has been found in 40% of OCCC [130]. 
Finally, AKT2 amplification was observed in 14% of OCCC [131]. It is still unclear if aberrations in 
the PI3K/AKT pathway are critical drivers of cancer growth and, therefore, a possible therapeutic 
target in ovarian cancers [128]. Nevertheless, preclinical and clinical phase-I studies have suggested 
that inhibition of this pathway may help to overcome resistance to chemotherapy in ovarian cancer [132], 
which is a common problem in OCCC and, therefore, would be of specially great interest in this  
tumor type [52]. 
3.4. PIK3CA Mutations in Endometriosis-Associated Ovarian Cancer and Endometriosis 
PIK3CA mutations, as a common mechanism of PI3K/AKT pathway activation in OCCC [133], will be 
discussed here in detail, since they are frequently associated with ARID1A mutations (cf. Section 4.2.). 
Activating mutations in the PIK3CA gene, encoding the p110α subunit of PI3K, have been observed 
at a frequency of 33%–40% in OCCC [2,129]. Kuo et al. [129] first reported the high frequency of 
activating PIK3CA mutations in a large cohort of 97 OCCC, including 18 affinity-purified tumor cells 
from fresh specimen, 69 samples of microdissected paraffin-embedded tumors and 10 OCCC cell 
lines. They described an overall frequency of 33% PIK3CA mutations and of 46% in the 28  
affinity-purified OCCCs and OCCC cell lines. The majority of the PIK3CA mutations were confined 
to exons 9 and 20, leading to an activation of p110α kinase. This was confirmed by 
immunohistochemistry, demonstrating an intense diffuse phosphorylated AKT immunoreactivity in all 
of the 18 specimens with PIK3CA mutations. This was also observed in PIK3CA wild-type tumors in 
34 (85%) of 40 cases, indicating that other mechanisms are contributing to AKT phosphorylation in a 
large proportion of OCCCs with wild-type PIK3CA [129]. 
Yamamoto et al. [134] sequenced exon 9 and 20 of PIK3CA in 23 OCCC samples and found 10 
tumors (43%) with activating mutations (H1047R in all cases). Interestingly, they observed the same 
mutations not only in nine adjacent atypical endometrioses of the 10 cases (90%), but they found  
non-atypical endometriotic tissue in six of the 10 samples (60%) with the same H1047R mutation, 
suggesting that these mutations occur very early in the tumorigenesis of OCCC [134]. 
An overview of studies that investigated PIK3CA mutations in OCCC and EnOC, as well as in 
endometriosis, is given in Tables 3 and 4, respectively. 
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Table 3. PIK3CA mutations in OCCC and EnOC. 
Authors, year of 
publication 
Samples PIK3CA mutations Ref. 
Campbell et al., 
2004 
167 primary epithelial ovarian carcinomas, of which, 
40 were samples of EnOC and OCCC and 88 were 
samples of serous ovarian carcinomas (all coding 
exons of PIK3CA analyzed) 
PIK3CA mutations in 8 (20%) of 40 EnOC and OCCC 
compared to only 2 (2.3%) of 88 in serous ovarian carcinomas 
(p = 0.001); mutation or gene amplification of PIK3CA was 
found in a total of 45% of OCCC and EnOC 
[135] 
Wang et al., 2005 
109 advanced ovarian carcinomas, including inter alia 
2 OCCC and 5 EnOC, as well as 90 serous and 4 
mucinous ovarian carcinomas (PIK3CA exon 9 and  
20 analyzed) 
A total of 4 activating missense PIK3CA mutations in 109 
tumors were found (in 1 of 2 OCCC, 1 mucinous and 2 serous 
ovarian carcinomas) 
[136] 
Levine et al., 
2005 
198 unselected invasive epithelial ovarian carcinomas 
(exon 9 and 20 analyzed) 
PIK3CA mutations in 24 of 198 (12%) ovarian carcinomas  
(not significantly different between different  
histological subtypes) 
[137] 
Willner et al., 
2007 
12 OCCC, 26 EnOC and 51 serous  
ovarian carcinomas 
Mutations in 3 of 12 (25%) OCCC, in 3 of 26 (12%) EnOC, but 
in none of 51 serous ovarian carcinomas 
PIK3CA gene amplification found in 0/22 EnOC and OCCC 
compared to 19/94 (20%) in SC 
[138] 
Kuo et al., 2009 
97 OCCC (18 OCCC with affinity-purified tumor cells 
from fresh specimen, 69 microdissected tumors from 
paraffin tissues, 10 tumor cell lines) 
PIK3CA mutations in 33% of the 97 OCCC (46% of the 28 
affinity-purified OCCC and OCCC cell lines) [129] 
Jones et al., 2010 
Whole exome sequencing in 8 OCCC samples and 
validation in 42 OCCC (including the 8 tumor samples of 
the discovery cohort) by Sanger sequencing of all exon 
Mutations of PIK3CA in 40% of the 42 tumors (a total of 17 
mutations), the majority at codons 542, 545, 546 or 1,047 [2] 
Yamamoto et al., 
2011 
23 OCCC (sequencing of PIK3CA exons 9 and 20) PIK3CA mutations in 10 (43%) of 23 OCCC (H1047R 
mutations in the kinase domain in all cases) 
[134] 
Yamamoto et al., 
2012 
42 OCCC (28 endometriosis-associated cases and 14 
clear-cell adenofibroma-associated carcinoma cases 
(sequencing of exons 9 and 20) 
17 (40%) of the 42 OCCC harboring PIK3CA mutations 
(majority of them ARID1A-deficient carcinomas (71%),  
suggesting frequent co-occurrence of mutations in these two genes 
[101] 
Yamamoto et al., 
2012 
90 cases of OCCC (including 42 cases previously examined 
in [101]; sequencing of PIK3CA exons 9 and 20) 
PIK3CA mutations found in 34 (39%) of 88 informative  
OCCC cases 
[102] 
Rahman et al., 
2012 
Mutational analysis of PIK3CA (exons 1, 9, 20) and 
immunohistochemistry for phospho-AKT and -mTOR 
in 56 OCCC samples 
13 ovarian carcinoma cell lines (4 serous, 9 clear cell) 
for in vitro inhibitor studies 
Missense mutations in 16 (28.6%) of 56 OCCC tumor samples 
No correlation of PIK3CA mutations with the 
immunohistochemical pattern of phosphorylated AKT or mTOR 
No correlation of PIK3CA mutations with sensitivity to 
PI3K/AKT/mTOR inhibitors in OCCC cell lines 
[139] 
McConechy et al., 
2013 
Select exon capture sequencing in 33 EnOC samples in 
addition to 307 endometrial  
endometrioid carcinomas 
12 (40%) of 30 EnOC mutated in PIK3CA. 107 (39%) of  
307 low-grade endometrial endometrioid carcinomas  
mutated in PIK3CA 
[140] 
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Table 4. PIK3CA mutations in endometriosis. 
Authors, year of 
publication 
Samples PIK3CA mutations Ref. 
Laudanski et al., 
2009 
Gene expression study using micro fluidic gene array 
in eutopic endometrium of 40 women with 
endometriosis and 41 controls without endometriosis 
PIK3CA expression in ovarian endometriosis significantly 
increased compared to endometrium of same patient. PIK3CA 
in endometrium of patients with endometriosis expressed at 
same level as in control endometrium. No mutations examined 
[116] 
Yamamoto et al., 
2011 
Tumor-adjacent endometriotic epithelium in 10 (of 
totally 23 OCCC) that harbored mutations in PIK3CA 
(sequencing of PIK3CA exons 9 and 20) 
Same H1047R mutation found in endometriotic epithelium 
adjacent to OCCC in 9 (90%) of 10 cases 
In 6 of the 9 lesions, the same mutation was found even in non-
atypical endometriotic epithelium, indicating that PIK3CA are 
occurring very early in the tumorigenesis of OCCC 
[134] 
Vestergaard et al., 
2011 
23 ectopic endometriotic samples (PIK3CA exon 9  
and 20) 
No PIK3CA mutations detected in this collective 
[141] 
3.5. Targeting the PI3K/AKT-Pathway in OCCC and EnOC 
PI3K/AKT/mTOR signaling is frequently altered in EnOC and OCCC, but it is unclear whether 
these genetic changes are critical drivers for these carcinomas. It is therefore questionable whether 
these molecules are susceptible to targeted inhibition and suitable for response prediction. Several 
PI3K/AKT/mTOR inhibitors were explored as single agents or in combination in clinical trials of 
different tumor types. In ovarian and endometrial cancers, significant single-agent activity with 
PI3K/AKT inhibitors is rarely observed [142,143]. However, it is known that PI3K/AKT activation 
contributes to a reduced response to chemotherapy in ovarian cancer [144] and that modulation of the 
PI3K/AKT/mTOR pathway is suitable for overcoming resistance to chemotherapy [132]. Thus, 
Mabuchi et al. demonstrated increased sensitivity of cisplatin-resistant OCCC cell lines to the mTOR 
inhibitor everolimus, compared to the cisplatin-sensitive parental OCCC cell lines [145]. 
To date, reliable biomarkers for the prediction of response to therapy in ovarian cancer are not in 
clinical use [146]. In the past, several studies have explored the effects of PI3K/AKT/mTOR inhibitors 
on human cancer cells. In a study of several OCCC cells, PIK3CA mutations did not predict the 
sensitivity to PI3K/AKT/mTOR inhibitors [139]. In contrast, activated AKT was a predictive marker 
of drug sensitivity in ovarian cancer cells, which were treated with RAD001 (everolimus) to inhibit the 
mTOR pathway [147]. 
In a recent study, seven patients with advanced ovarian carcinomas harboring a PI3KCA mutation 
were enrolled onto clinical trials that included a PI3K/AKT/mTOR inhibitor. Prior to that, all patients 
had experienced treatment failure with standard therapies. Two patients (2/7, 29%) responded to this 
targeted therapy, which was combined with a cytotoxic drug. Other gynecologic and breast carcinomas 
in this study cohort also demonstrated a higher response rate than patients without PIK3CA mutations. 
Despite the small sample size, the authors conclude that PIK3CA mutation screening is helpful in the 
use of PI3K/AKT/mTOR pathway inhibition. However, single-agent use seems to not be sufficient to 
induce a response, because PIK3CA mutations often coexist with other concurrent molecular 
aberrations. Interestingly, both responders of the ovarian cancer subset had a simultaneous MAPK 
pathway mutation (one each in KRAS and BRAF) [142]. 
It is known that PI3K/AKT/mTOR signaling is a complex process, which interacts with the 
RAS/RAF/MEK/ERK pathway. In this context, it was observed that PIK3CA mutations may predict 
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the response to PI3K/AKT/mTOR inhibitors, whereas concomitant mutations in the MAPK pathway 
(KRAS, NRAS, BRAF) may mediate resistance [148,149]. Therefore, clinical trials investigate several 
strategies, like dual targeting of PI3K/AKT/mTOR and RAF/MEK/ERK pathways, as well as the 
combination of multi-drugs instead of single-agents [128,150]. 
4. Further Implications 
4.1. Functional Studies about the Loss of ARID1A Expression In Vitro and In Vivo 
Cancer genome sequencing studies have created a new perspective about disordered chromatin 
organization as a feature of cancer, showing that mutations of epigenetic regulators are occurring 
frequently in a wide variety of different human cancers. Although the subject of intensive study, the 
exact function and role of ARID1A as a tumor suppressor remains far from being elucidated. In vitro 
studies have suggested different roles for ARID1A to exert its tumor suppressive action, which are 
mainly through proliferation, differentiation and apoptosis [77]. Knockdown of ARID1A led to 
increased proliferation of normal ovarian surface epithelial cells [84] and disrupted differentiation of 
certain cell types (e.g., osteoblasts) [151]. In Jurkat leukemia cells, Fas-mediated cell death was 
inhibited after ARID1A knockdown [152]. ARID1A, in contrast to the mutually exclusive ARID1B 
subunit of the SWI/SNF complex, inhibited cell cycle arrest in murine preosteoblasts [153,154]. 
Although these findings all constitute promising new perspectives in understanding the function of 
ARID1A as a tumor suppressor, the functional consequences of ARID1A mutations are probably more 
vast, since ARID1A regulates hundreds of different genes through the SWI/SNF chromatin remodeling 
complex [80]. Furthermore, it is likely that ARID1A mutations have divergent effects, depending on 
different cell and tumor types in which they are present, probably also depending on the mutational 
landscape in different cancer types. As a result, functional studies of ARID1A present a substantial 
scientific challenge [77]. 
4.2. Evidence for Cooperative Mechanisms between ARID1A and the PI3K/AKT Pathway 
Various studies are suggesting cooperating mechanisms in relation to ARID1A mutations. 
Yamamoto et al. described a frequent co-occurrence between activating PIK3CA mutations and loss of 
ARID1A expression in OCCC, demonstrating that 46% of ARID1A deficient tumors were harboring 
PIK3CA mutations versus 17% of the ARID1A expressing tumors [102]. In endometrioid endometrial 
cancer, a higher frequency of PI3K/AKT-pathway alterations (PTEN loss or PIK3CA activating 
mutations) was found in tumors with a loss of ARID1A expression, and the number of tumors that 
showed no alteration in the PI3K/AKT-pathway was 4.6-fold higher in tumors with preserved 
ARID1A expression (p = 0.042) [107]. An association between PIK3CA and ARID1A mutations has 
also been reported in gastric cancer [92]. 
It has been suggested in many studies that loss of ARID1A is usually associated with TP53  
wild-type tumors [84,91,92,155], and one study showed evidence for a direct protein-protein 
interaction between ARID1A and p53 [84]. 
A very interesting study conducted by Liang et al. [156] not only identified ARID1A as a potential 
driver gene in endometrial cancer, but also demonstrated that ARID1A mutations frequently co-occur 
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with mutations, leading to activation in the PI3K/AKT pathway. An important observation was that 
siRNA knockdown of ARID1A in endometrial cancer cell lines per se led to an increased 
phosphorylation of AKT, indicating a regulation of the PI3K/AKT pathway activity by ARID1A [156]. 
A recent study in SMARCB1, a potent tumor suppressor with loss of expression, especially in 
certain rhabdoid tumor types and which is a core subunit of the SWI/SNF complex, showed persistent 
activation of AKT in SMARCB1-deficient tumor cells, contributing to survival and proliferation. 
Inhibition of AKT was sufficient to inhibit development of SMARCB1-deficient xenograft-tumors and 
to inhibit proliferation of SMARCB1-deficient cells in vitro [157]. 
Remarkable results have been presented at the 104th Annual Meeting of the American Association 
for Cancer Research by Guan et al. [158]: The authors tested the possibility of molecular dependency 
of ARID1A and the PI3K/PTEN pathway in an ARID1A knockout mice and ARID1A/PTEN double 
knockout mice model. After conditional depletion of either ARID1A (n = 10) or simultaneously 
ARID1A and PTEN (n = 12), the mice with knock-out of only ARID1A did not develop histological 
alterations, whereas 40% of the mice with double knock-out of ARID1A and PTEN developed poorly 
differentiated ovarian tumors disseminating in the peritoneal cavity and ascites. In the other 60%, the 
authors found hyperplasia of the ovarian surface epithelium. This shows that ARID1A inactivation in 
itself is not sufficient to initiate tumor development and requires a second hit, possibly consistent with 
an alteration in the PI3K/PTEN/AKT pathway to lead to carcinogenic transformation [158]. 
These observations are exciting for at least two important reasons. Firstly, it may  
explain the observation of ARID1A expression in non-atypical endometriosis made by several  
groups [101,104,106]; loss of ARID1A expression may be an early molecular event in these cases that 
might increase the overall risk of developing endometriosis-associated cancer, but in itself is not 
sufficient to initiate cancerogenesis. Secondly, it confirms that there is a close cooperative mechanism 
between ARID1A mutations and PI3K/AKT pathway alterations that might be of importance for early 
tumor detection, as well as in a therapeutic context. Interdependency on PI3K/AKT activation of 
ARID1A mutated tumor clones might be a process that is targetable by small-molecule inhibitors of the 
PI3K/AKT/mTOR pathway. 
4.3. Possible Clinical Implications of ARID1A Mutations 
The question of clinical implication of ARID1A mutations is not yet thoroughly answered. Whilst 
there is fast growing knowledge about the distribution of mutations of ARID1A and other members of 
the SWI/SNF complex in various cancers, functional and clinic-pathological data remain quite sparse. 
Many studies have investigated ARID1A mutations as prognostic markers in a multitude of different 
cancers, such as OCCC, as well as breast, gastric and bladder cancer [91,93,97,100,102,155,159–161], 
but to date, none have demonstrated a consistent prognostic significance of ARID1A mutational or 
expressional status. This may be partially due to the lack of larger prospective studies [77]. On the 
other hand, it has also to be answered if an early loss of ARID1A expression and/or PIK3CA mutation 
represents an increased probability for developing OCCC or EnOC in endometriosis [3,101,104,106]. 
Last, but not least, it will be of major interest to determine whether ARID1A inactivation may be 
therapeutically exploited by targeting downstream and potentially reversible epigenetic gene 
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expression targets altered by remodeler mutations, such as, e.g., oncogenic proteins cyclin D1 and 
MYC or alterations in the Hedgehog pathway signaling [77,133,162]. 
An interesting synthetic-lethality therapy principle involving the SWI/SNF catalytic subunit, 
BRG1/SMARCA4, frequently deficient in non-small-cell lung carcinomas by BRM-ATPase inhibitors 
targeting another SWI/SNF subunit, has been proposed in a recent study [163]. This demonstrates that 
although the effects of SWI/SNF subunit mutations are very complex and still poorly understood, their 
respective downstream effectors are potentially targetable by compounds, opening a wide horizon of 
mechanisms that may be influenced for therapeutic purposes. 
5. Conclusions 
Although still at the beginning, the current genomic characterizations of ARID1A mutations and 
functional investigations of the loss of ARID1A expression in vitro and in animal studies, combined 
with analyses of presumed cooperating pathways as, e.g., the PI3K/AKT/mTOR pathway through 
direct activation and mutations of PTEN or PIK3CA, opens new perspectives for potential therapeutic 
approaches. This is of great interest in OCCC, since this frequently endometriosis-associated ovarian 
carcinoma subtype is characterized by resistance to conventional chemotherapy regimens and, 
therefore, has a poor prognosis in advanced stages. Mutations and consecutive loss of ARID1A 
expression, as well as activating mutations in the PI3K/AKT pathway (through loss of PTEN 
expression or PIK3CA activation) are highly frequent in OCCC and have to be further assessed in 
potential therapeutic strategies. The current intensified research activity in this field promises 
improved understanding and relevant progress in clinically significant aspects in the near future. 
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